Shots:

• Voluntis enters into a license agreement with Eisai to design & develop DTx for patients and healthcare professionals to support cancer treatment- utilizing the Theraxium technology platform
• The DTx will be designed with the intent to be commercialized in the US- Japan and EU- which will boost Voluntis’ pipeline and global footprint
• Additionally- the partners will explore other opportunities to develop- evaluate and commercialize DTx in the field of neurology- notably AD and dementia

  Ref: Businesswire | Image: Voluntis